Recruiting
Chronic kidney disease
RecruitingRandomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease
Registered drug
Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease
Registered drug
- Disease:Chronic kidney disease
- Substances:AZD5004Dapagliflozin
Countries:
Poland
Poland- Participants:18–64 years · 65+ years
- Substances:AZD5004
- Sponsor:AstraZeneca AB



